Jefferies Lifts Price Target on ZIOPHARM (ZIOP) After Analyst Day

Jefferies boosted its price target on ZIOPHARM Oncology (NASDAQ: ZIOP) from $6 to $7 following the comapny's recent R&D day.

At the event the company highlighted: (1) palifosfamide in STS and SCLC; (2) PFS as a validated endpoint for FDA full approval: & (3) early IL-12 DNA therapeutics.

The firm comments, "ZIOP expects Ph3 palifosfamide PFS data in 1st-line sarcoma by YE12, with Ph3 SCLC data in ~2014-2015. On recent FDA full approval of Votrient in Tx-experienced sarcoma, it notes FDA's clear policy shift in favor of PFS benefits for full approvability."

For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.

Shares of ZIOPHARM Oncology closed at $5.89 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tractor Supply Company (TSCO) PT Lowered to $33 at UBS
• Sasol Ltd. (SOL:SJ) (SSL) PT Lowered to ZAR174 at Goldman Sachs
• UBS Starts Elevra Lithium (ELV:AU) at Buy